SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity

•Understanding the crosstalk between SARS-CoV-2 and the innate immune system.•Two SARS-CoV-2 S protein peptides capable of binding to the NKG2D receptor of natural killer (NK) cells are identified.•These peptides activate NK cells and stimulate IFN-γ production. Immune dysregulation is commonly obse...

Full description

Saved in:
Bibliographic Details
Published inCellular immunology Vol. 371; p. 104454
Main Authors Kim, Hanna, Byun, Jae-Eun, Yoon, Suk Ran, Koohy, Hashem, Jung, Haiyoung, Choi, Inpyo
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.01.2022
The Author(s). Published by Elsevier Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:•Understanding the crosstalk between SARS-CoV-2 and the innate immune system.•Two SARS-CoV-2 S protein peptides capable of binding to the NKG2D receptor of natural killer (NK) cells are identified.•These peptides activate NK cells and stimulate IFN-γ production. Immune dysregulation is commonly observed in patients with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces severe lung inflammation and innate immune cell dysregulation. However, the precise interaction between SARS-CoV-2 and the innate immune system is currently unknown. To understand the interaction between SARS-CoV-2 and natural killer (NK) cells, several SARS-CoV-2 S protein peptides capable of binding to the NKG2D receptor were screened by in silico analysis. Among them, two peptides, cov1 and cov2, bound to NK cells and NKG2D receptors. These cov peptides increased NK cytotoxicity toward lung cancer cells, stimulated interferon gamma (IFN-γ) production by NK cells, and likely mediated these responses through the phosphorylation of Vav1, a key downstream-signaling molecule of NKG2D and NK activation genes. The direct interaction between SARS-CoV-2 and NK cells is a novel finding, and modulation of this interaction has potential clinical application as a therapeutic target for COVID-19.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0008-8749
1090-2163
DOI:10.1016/j.cellimm.2021.104454